2026-04-14T18:14:21Zhttps://uvadoc.uva.es/oai/requestoai:uvadoc.uva.es:10324/602632025-01-13T10:49:13Zcom_10324_1138com_10324_931com_10324_894col_10324_1226
Maza Solano, Juan
Calvo Henríquez, Christian
Alobid, Isam
Álvarez Cendrero, Marta
Palomares, Óscar
Moreno Luna, Ramón
Santos Pérez, Jaime
González García, Jaime
Sánchez Gómez, Serafín
2023-07-13T08:23:17Z
2023-07-13T08:23:17Z
2022
Journal of Clinical Medicine, 2022, Vol. 11, Nº. 23, 7056
2077-0383
https://uvadoc.uva.es/handle/10324/60263
10.3390/jcm11237056
7056
23
Journal of Clinical Medicine
11
2077-0383
Producción Científica
Currently, some monoclonal antibodies (mAbs) are being studied for chronic rhinosinusitis with nasal polyps (CRSwNP). Three anti-IL-5 mAb: mepolizumab, reslizumab and benralizumab, have been tested through randomized clinical trials. In this real-life study, we aimed to describe the nasal effects of a cohort of asthmatic adults treated with anti-IL-5 mAb. Methods: We carried out an observational study in adults (≥18 years) on anti-IL-5 mAb treatment. Variables included ACT and SNOT−22 questionnaires, nasal polyps score, blood total IgE levels and blood eosinophil count. Results: Overall, 38 participants were included in the study; 19 patients received mepolizumab, 17 were treated with benralizumab and 2 patients were given reslizumab. There was a statistically significant difference in the ACT and SNOT−22 scores before and after mAb treatment. ACT score increased from 11.05 to 21.5 after treatment (p < 0.001). SNOT−22 decreased from 57 to 37.3 after treatment (p = 0.004). No statistically significant differences between mAb groups were observed regarding the ACT or the SNOT−22 (p = 0.775) response (p = 0.775). In addition, 60.53% of patients obtained a minimal clinically important difference (MCID) in SNOT−22. Conclusions: A significant clinical response based on SNOT−22 score evolution after anti-IL-5 mAb treatment was observed. This study also demonstrated that blood eosinophil count, rather than serum total IgE levels, is the best predictor of asthma symptom improvement, which was assessed through the ACT and SNOT−22 questionnaires.
application/pdf
eng
MDPI
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
Asthma
Asma
Allergy
Otorhinolaryngology
Otorrinolaringologia
Chronic diseases
Enfermedades crónicas
Respiratory organs - Diseases
Respiratorio, aparato - Enfermedades
Pneumology
Neumología
Nose - Diseases
Nariz - Enfermedades
Asthma - Treatment
Asma - Tratamiento
3207.01 Alergias
3205.08 Enfermedades Pulmonares
Nasal symptoms in asthmatic patients under treatment with anti-IL-5 monoclonal antibodies. A real-life cohort study
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
https://www.mdpi.com/2077-0383/11/23/7056
SI